What is an Evidence Summary?
Key messages from scientific research that's ready to be acted on
Got It, Hide this
In people with advanced non-small cell lung cancer, combined with other medications, carboplatin and cisplatin do not differ for overall or 1-year survival
de Castria TB, da Silva EMK, Gois AFT, et al.. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer. Cochrane Database Syst Rev. 2013:8:CD009256.
How effective and safe is carboplatin compared with cisplatin in people with advanced non-small cell lung cancer?
2 major types of lung cancer are small cell lung cancer and non-small cell lung cancer. About 85 to 90% of lung cancers are non-small cell lung cancer.
Newer anticancer medications with different action mechanisms (third-generation drugs) are available. These medications—in combination with cisplatin—are standard chemotherapy for advanced non-small cell lung cancer. However, carboplatin chemotherapy may have a different toxicity profile.
The aim of treatment for people with advanced non-small cell lung cancer is only to provide relief from pain and distress.
How the review was done
This systematic review included 10 randomized controlled trials of 5,017 people aged 18 to 75 years with advanced non-small cell lung cancer. The publication period was 2001 to 2011.
Carboplatin was compared with cisplatin—both in combination with a third-generation drug (gemcitabine, paclitaxel, or docetaxel).
Outcomes were overall survival, 1-year survival rate, quality of life, and toxic effects.
What the researchers found
- Carboplatin and cisplatin—both in combination with a third-generation drug—did not differ in overall survival.
- Carboplatin and cisplatin—both in combination with a third-generation drug—did not differ in 1-year survival.
- Cisplatin caused about 2.3 times more nausea or vomiting events, or both, than carboplatin.
- Carboplatin caused about 2 times more low platelet count events (which can cause bleeding) than cisplatin.
- Carboplatin caused about 1.5 times more nerve toxicity events (which cause numbness or pain) than cisplatin.
- Carboplatin and cisplatin did not differ for anemia, skin rash, white blood cell deficiency, hair loss, or kidney toxicity.
In people with advanced non-small cell lung cancer, combined with a third-generation drug, carboplatin and cisplatin do not differ for overall and 1-year survival.
Cisplatin causes more nausea or vomiting. Carboplatin causes more low-platelet count and nerve toxicity events.
Randomized controlled trials
Studies where people are assigned to one of the treatments purely by chance.
A comprehensive evaluation of the available research evidence on a particular topic.
Related Evidence Summaries
Cochrane Database of Systematic Reviews (2018)
Patient Education and Counseling (2018)
Cochrane Database of Systematic Reviews (2016)
Related Web Resources
Health Link B.C.
Colorectal testing every 1-2 years is recommended for people between ages 50 and 74. Your doctor may recommend screening before age 50 and more often if you have an increased risk of this type of cancer (eg. family history of colon cancer, polyps or Crohn's disease).
Canadian Task Force on Preventive Health Care
Women ages 50-74 should have a mammogram every 2 to 3 years, if they are not at high risk of breast cancer. Discuss with your doctor whether you should have a mammogram if you are over age 75.
Dance therapy does not appear to have a large benefit on improving physical or psychological symptoms of people with cancer, such as depression, fatigue or body image. However, you should dance if it helps you feel better.
DISCLAIMER These summaries are provided for informational purposes only. They are not a substitute for advice from your own health care professional. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the McMaster Optimal Aging Portal